Bivalirudin
Based on 10 publication(s) in Google Scholar
Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others.
For research use only. We do not sell to patients.
- Purity: 99.97%
- CAS No.: 128270-60-0
- Formula: C98H138N24O33
- Molecular Weight:2180.29
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Bivalirudin
More- Compos B Eng. 2024 Aug 15.
- Compos B Eng. 1 April 2022, 109702.
- Allergy. 2022 Jul;77(7):2104-2120. [Abstract]
- Antiviral Res. 2023 Jun:214:105606. [Abstract]
- Coatings. 2026 Apr;16(4):483.
- J Am Soc Mass Spectrom. 2020 Jul 5. [Abstract]
- J Clin Pathol. 2019 Dec;72(12):817-824. [Abstract]
- Int J Auto Tech-Jpn. 2020 Jan.
- bioRxiv. 2025 Sep 26.
- Elife. 2022 Mar 23:11:e77444. [Abstract]
Biological Activity
|
IL-6 |
IL-5 |
Bivalirudin (30 μg/mL; 10 min) inhibits Thrombin (HY-114164)-induced S1PR2 upregulation and endothelial hyperpermeability, and reverses the abnormal distribution of cytoskeletal proteins and β-catenin in HUVECs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HUVECs treated Thrombin (HY-114164)
-
Concentration:30 μg/mL
-
Incubation Time:10 min
-
Result:Inhibited the level of S1PR2.
Bivalirudin (2 mg/kg; intravenous injection; single dose) inhibits thrombosis in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice aged 5-7 days old treated respiratory syncytial virus (RSV)[2]
-
Dosage:2 mg/kg
-
Administration:Intravenous injection; every other day; 2 weeks
-
Result:Significantly reduced cellular infiltration, inflammatory cytokines (e.g., IL-5, IL-6, CXCL1), and abnormal clotting parameters (e.g., D-dimer, soluble thrombomodulin) in RSV-infected lungs.
Normalized viral copy numbers and reversed histopathological changes such as nuclear pyknosis in pneumocytes.
-
Animal Model:P2Y12-- and WT mice with thrombosis induced by perfusion through type III collagen- or tissue factor-coated capillary chambers, and P2Y12+- mice with mesenteric artery injury induced by 12.5% FeCl3 solution[3]
-
Dosage:2 mg/kg
-
Administration:Intravenous injection; single dose
-
Result:Significantly inhibited thrombus volume in P2Y12-- mice in the type III collagen-induced thrombosis model but had no significant effect in wild-type mice.
Inhibited thrombosis in both WT and P2Y12-- mice in the tissue factor-induced thrombosis model.
Delayed the time of thrombus appearance and vessel occlusion, but could not completely prevent vessel occlusion in wild-type mice in the FeCl3-induced mesenteric artery injury model in P2Y12+- mice.
Chemical Information
-
CAS No. 128270-60-0
-
Appearance Solid
-
Molecular Weight 2180.29
-
Formula C98H138N24O33
-
Color White to off-white
-
Sequence
{d-Phe}-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-ILE-Pro-Glu-Glu-Tyr-Leu
-
Sequence Shortening
{d-Phe}-PRPGGGGNGDFEEIPEEYL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
-
-
Allergy
2022 Jul;77(7):2104-2120. PMID: 34995358 -
Antiviral Res
Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2. [Abstract]2023 Jun:214:105606. PMID: 37076089 -
-
J Am Soc Mass Spectrom
Wire Desorption Combined with Electrospray Ionization Mass Spectrometry: Direct Analysis of Small Organic and Large Biological Compounds. [Abstract]2020 Jul 5. PMID: 32559077 -
J Clin Pathol
Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays. [Abstract]2019 Dec;72(12):817-824. PMID: 31366633 -
-
-
Elife
2022 Mar 23:11:e77444. PMID: 35294338
Solvent & Solubility
H2O : 10 mg/mL (4.59 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ye H, et al. Bivalirudin Attenuates Thrombin-Induced Endothelial Hyperpermeability via S1P/S1PR2 Category: Original Articles. Front Pharmacol. 2021 Aug 3;12:721200. [Content Brief]
[2]. Zhuang S, et al. Bivalirudin exerts antiviral activity against respiratory syncytial virus-induced lung infections in neonatal mice. Acta Pharm. 2022 Apr 13;72(3):415-425. [Content Brief]
[3]. André P, et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.Circulation. 2003 Nov 25;108(21):2697-703. [Content Brief]
[4]. Warkentin TE, et al. Bivalirudin: a review. Expert Opin Pharmacother. 2005 Jul;6(8):1349-71. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.4587 mL | 2.2933 mL | 4.5865 mL | 11.4664 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Bivalirudin Related Classifications
HY-P1929 Related Classifications
Powered by Bioz